2. Vitamin D Related/Nuclear Receptor
  3. Estrogen Receptor/ERR
  4. Camizestrant

Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER+ HER2-advanced breast cancer.

For research use only. We do not sell to patients.

CAS No. : 2222844-89-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Camizestrant Related Antibodies

Top Publications Citing Use of Products

    Camizestrant purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Nov 19.  [Abstract]

    Immunoblots showing levels of ER, GR and ERK2 (loading control) in MCF-7 D538G cells treated with Dex (700 nM), Fulvestrant (1 μM), Camizestrant (1 μM) or Elacestrant (1 μM) for 72 h.

    Camizestrant purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Nov 7;9(1):343.  [Abstract]

    Efficacy of increasing concentrations of Camizestrant (10 μM; 6 days) over a backbone of fixed palbociclib and rogaratinib in the ESR1-mutant PDO.

    Camizestrant purchased from MedChemExpress. Usage Cited in: Harvard University.  2023 Mar. 30487357.

    UPS-focused CRISPR degradation screen for ERα-eGFP stability in K562-Cas9 cells treated with Camizestrant at 1 μM for 16 h (n=3).

    Camizestrant purchased from MedChemExpress. Usage Cited in: Harvard University.  2023 Mar. 30487357.

    Flow analysis of ERα-eGFP degradation in K562-Cas9 cells transduced with indicated shRNA and treated with fulvestrant, elacestrant, amcenestrant, Camizestrant, giredestrant at 1 μM, or brilanestrant, AZD9496, LSZ-102 at 5 μM, or estradiol at 1 μM, or ARV-471 at 0.1 μM for 16 h (n = 3). Cells were starved for 48 h prior to compound treatment.

    Camizestrant purchased from MedChemExpress. Usage Cited in: Harvard University.  2023 Mar. 30487357.

    Luciferase assay results of ERE activation in T47D-Cas9 cells that were treated with DMSO or indicated SERDs (Camizestrant, ect.) at 1 μM for 6 h (n=3). Cells were starved for 48 h prior to compound treatment. ERE activation was normalized using DMSO control.

    View All Estrogen Receptor/ERR Isoform Specific Products:

    View All Isoforms
    Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER+ HER2-advanced breast cancer[1].

    IC50 & Target

    IC50: estrogen receptor (ER)[1]
    In Vitro

    Camizestrant is extracted from patent US20180111931A1, example 17[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Camizestrant Related Antibodies
    In Vivo

    Camizestrant (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft[1].
    Camizestrant (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells in female NSG mice[1]
    Dosage: 0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg
    Administration: Oral administration; 30 days; once daily
    Result: Inhibited tumor growth in a dose-dependent manner.
    Clinical Trial
    Molecular Weight

    476.51

    Formula

    C24H28F4N6
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    FC(F)(F)CN1[C@H](C2=CC=C(NC3CN(CCCF)C3)C=N2)C4=C(C5=C(NN=C5)C=C4)C[C@H]1C
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (209.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0986 mL 10.4930 mL 20.9859 mL
    5 mM 0.4197 mL 2.0986 mL 4.1972 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 7.5 mg/mL (15.74 mM); Clear solution

      This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 7.5 mg/mL (15.74 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.32%

    SDS (393 KB)

    COA (251 KB) HNMR (244 KB) RP-HPLC (206 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.0986 mL 10.4930 mL 20.9859 mL 52.4648 mL
    5 mM 0.4197 mL 2.0986 mL 4.1972 mL 10.4930 mL
    10 mM 0.2099 mL 1.0493 mL 2.0986 mL 5.2465 mL
    15 mM 0.1399 mL 0.6995 mL 1.3991 mL 3.4977 mL
    20 mM 0.1049 mL 0.5246 mL 1.0493 mL 2.6232 mL
    25 mM 0.0839 mL 0.4197 mL 0.8394 mL 2.0986 mL
    30 mM 0.0700 mL 0.3498 mL 0.6995 mL 1.7488 mL
    40 mM 0.0525 mL 0.2623 mL 0.5246 mL 1.3116 mL
    50 mM 0.0420 mL 0.2099 mL 0.4197 mL 1.0493 mL
    60 mM 0.0350 mL 0.1749 mL 0.3498 mL 0.8744 mL
    80 mM 0.0262 mL 0.1312 mL 0.2623 mL 0.6558 mL
    100 mM 0.0210 mL 0.1049 mL 0.2099 mL 0.5246 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Camizestrant Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Camizestrant2222844-89-3AZD-9833AZD9833AZD 9833Estrogen Receptor/ERRMCF-7breastcancertumorCTC174metastaticER+ESR1Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Camizestrant
    Cat. No.:
    HY-136255
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.